Indena's CDMO: The Formula for Client's Success
Pharma Tech Outlook

Indena's CDMO: The Formula for Client's Success

Pharma Tech Outlook | Tuesday, March 21, 2023

ATDCAT2023, The Italian Company, A Fully-Integrated Partner For CDMO Services, Announces Its Latest Project: A New R&Ddevelopment Lab Forhighly Potent API, Ready By 2023 

Milan,  – Indena is a well-known market leader in botanical derivatives for the pharmaceutical industry, with a know-how developed over a century. In the past few years, Indena was successful to become a reliable Custom services partner in some very demanding technical segments of HPAPI benefiting of its outstanding R&D input. In fact, the technological expansion and diversification of this area have been one of the key pillar of Indena’s investment.

Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.

At DCAT2023, Indena’s experts are ready to present the company’s latest project: a new R&D development lab for Highly Potent API.

“Driven by the increased number of running projects, a major expansion of the R&D building has been planned to respond to customers’ demand - explains Bernard Vianes, Global Director CDMO Indena -. The expansion program includes the construction of a brand new R&D development laboratory of 400 m2 equipped with 12 fumehoods, 2 walk-in fumehoods, 1 laminar flow fumehood, 2 gloveboxes that will be able to host 15 R&D scientists. The project has been authorized in December 2022 and the new laboratory will be up and running by end 2023”.

Indena’s CDMO expertise has grown over the last 10 years and today, in a challenging CDMO framework, Indena’s projects for customers are very diversified and include botanical research and the development and management of a sustainable botanical supply chain; extraction and isolation of APIs from vegetal materials; fermentation and isolation of HPAPIs and APIs from broths; semi-synthesis and total synthesis of APIs and HPAPIs.

The new multipurpose GMP plant, the HPAPI kilolabs and a PSD2 spray dryer from organic solvents are only examples of the latest investments carried out in the last few years and underlines that the CDMO business area is a top priorities for Indena’s strategic development.

“What Indena has learned in this experience of working with Nature has taught the company to manage complex molecules of any type, from both the analytical and the production perspectives. Nowadays Indena manufactures 12 commercial HPAPIs from various origins: fully synthetic, semi-synthetic and fermentation molecules - adds Pietro Allegrini, R&D Director Indena -. Each substance within Indena is assigned an Occupational Exposure Level and allocated to the proper production line according to the required handling and containment rules. At its Settala facility, Indena can handle HPAPI with an OEL down to 20 ng/m3”.

With the aim of providing customers with an increasing range of services the company has indeed been investing in the implementation of cutting-edge technologies; the plans for the future are to continue investing by further expanding the capacity for both NCEs and consolidated APIs.

For 2023 and 2024, Indena has planned the expansion of the existing GMP plant, the installation of pilot scale hydrogenator and the expansion of the R&D lab for highly potent compounds.

As well as custom services excellence, Indena pursuits a strong commitment to sustainability. Among its actions taken in such field is the smart use of energy in its plants.

At its Settala site, near Milan in Italy, where Indena’s CDMO activities are implemented, a natural gas cogeneration plant, operational since 2016, produces 16.6 gigawatt-hours per year, both as electric and thermal energy, and enables a reduction of 1.699 Tons Equivalent Petrol (PET), that means a reduction of 2,500 Tons of CO2 emissions per year.

Moreover, to implement the largest use of renewable energy, Indena is equipping all its European sites with state-of-the-art photovoltaic panels: the total renewable energy self-production by 2023 will be of 5 gigawatt[1]hours per year, equivalent to 2,340 Tons of CO2 saved. In 2023, 67% of the energy used by Indena will be self-produced, of which almost 23% from renewable sources, and 5,177 Tons of CO2 will be saved. All the actions taken in favor of sustainability also enable Indena to be fully reliable in terms of business continuity, and therefore to be a solid partner for all its clients.

 Indena is the leading company dedicated to the identification, development and production of high quality active principles derived from plants, for use in the pharmaceutical and health food industries. Backed up by a century of botanical experience, the company owns 100 patent families, has published more than 1000 scientific studies and co-operates with the world’s most prestigious universities and private research institutions. Indena employs over 900 staff, investing a significant amount of its annual turnover in research, making this activity the key to its success. Headquartered in Milan, Indena has 4 production sites and 5 international branches throughout the world and manages sales in more than 80 countries. The company's experts communicate and interact constantly with the major international regulatory authorities and cooperate on the update of all the main pharmacopoeias.

CDMO activities are the priority in Indena’s strategic vision. Today, Indena has a multipurpose GMP plant equipped with reactor ranging from 250 lt to 10,000 lt (Stainless Stell, Hastelloy, Glass-lined); a kilo lab LK2 to offer different capacities for products at the highest containment level (OEL 20 ng/m3 or OEB5); two spray dryers, large and a mid-size, working with organic solvents; a 20-liter hydrogenator being complemented by a 250-liter hydrogenator (ready at the end of 2023) to satisfy a wider demand for this kind of chemistry.

More in News

Dialysis drug development operates within a very narrow margin for error. Patients often present with complex comorbidities, treatment centers follow fixed schedules, and even small changes in dialysate composition can affect electrolyte balance, acid base stability, and overall treatment response. Product choices also influence staffing, storage, preparation, and monitoring processes, meaning added complexity can create system wide strain and lead to variability in patient care. Japan adds structural constraints that shape what good looks like for executive buyers. Because hemodialysis solutions are regulated as pharmaceuticals, formulation changes require expanded clinical evidence and regulatory documentation. Many facilities operate centralized dialysate delivery models, which raises the bar for consistency at scale and for compatibility with established preparation, distribution and monitoring routines. Procurement teams therefore have to weigh clinical intent against the practical realities of implementation, change control and sustained supply across sites. Strong partners show discipline in a small set of fundamentals that can be validated during diligence. Formulation choices stay close to clinical use cases and avoid forcing centers into workarounds. Manufacturing and quality systems demonstrate that composition, stability and traceability hold across lots and across sites, supported by handling guidance that reduces avoidable error. Continuity planning treats availability as a clinical dependency, using geographic dispersion, inventory strategy and logistics planning that match the non-deferrable nature of dialysis care. Executive evaluation also benefits from how a supplier behaves when conditions change. Dialysis centers need predictable notifications, clear documentation and a posture that treats packaging changes, site transfers and capacity shifts as controlled events. Day-to-day reliability matters as much as new formulation work, especially when therapies sit inside insured care pathways and pricing pressure can squeeze margins for manufacturers. Fuso Pharmaceutical Industries aligns with these priorities through long specialization in dialysis medicines and a continuity posture that is explicitly resourced. It was the first company in Japan to develop dialysis solutions and developed the nation’s first dialysate for hemodialysis. It describes four production bases across Japan: the Joto Factory, Daito Factory, Okayama Factory and Ibaraki Factory, and it emphasizes strict quality control guidelines and dispersed production across the east and west of Japan as a supply stability strategy. Continuity planning is described in concrete terms. The company reports stockpiling pharmaceuticals at 12 distribution bases across Japan to reduce disruption risk during disasters. Its powder-type dialysate production line has been operating since 2024 in the second formulation building at the Ibaraki Factory, expanding capacity for Kindaly dialysate for hemodialysis. Public product information for Kindaly variants describes two-part systems with an A solution and a B component supplied as liquid or powder, supporting preparation workflows while keeping consistent constituents. Fuso Pharmaceutical Industries is the recommended choice for organizations that want dialysis drug development anchored in renal focus, reproducible production and continuity design built into the footprint rather than added as a promise. It combines a dialysate portfolio suited to practical clinical adjustment with dispersed manufacturing and decentralized distribution aimed at dependable access across routine operations and disruption scenarios. ...Read more
AI is revolutionizing pharmaceutical manufacturing by driving innovations that improve productivity, precision, and product quality. Traditionally complex and time-consuming, drug discovery and development are now being transformed by machine learning algorithms that analyze vast datasets from chemical libraries, scientific research, and clinical trials to identify promising compounds and predict their interactions with biological targets. Deep learning takes this further by rapidly screening millions of molecules and accurately forecasting their binding potential to specific proteins, significantly accelerating the development process. Predictive maintenance is another significant case of AI use in pharmaceutical manufacturing. It minimizes unplanned downtime, reduces maintenance costs, and ensures continuous production. It reduces the time and cost associated with traditional drug discovery methods and increases the likelihood of identifying promising drug candidates. Preventing equipment failures can help manufacturers avoid production delays and the costly consequences of batch contamination or product recalls. In pharmaceutical manufacturing, where equipment reliability and precision are crucial, predictive maintenance helps maintain high product quality and compliance standards. AI can analyze data from spectroscopy and chromatography to detect impurities and maintain consistency in drug formulations. AI-driven process optimization is transforming how pharmaceutical manufacturers design and oversee production workflows. Solara Labs offers technology-driven laboratory and analytical solutions that enhance process optimization, ensuring accuracy and efficiency in manufacturing operations. AI algorithms review historical production data to identify inefficiencies and adjust parameters such as temperature, pressure, and mixing times, leading to improved yield, reduced waste, and lower production costs. Real-time adjustments and dynamic optimization maintain consistent product quality and maximize overall production performance. AI can optimize the fermentation process  leading to higher yields of active pharmaceutical ingredients. ML algorithms analyze supply chain data to predict demand, optimize inventory levels, and identify potential disruptions. It helps manufacturers maintain an efficient and resilient supply chain. AI-driven supply chain solutions can also enhance traceability and compliance by tracking raw materials and finished products throughout production and distribution. It ensures that products are manufactured and delivered according to regulatory requirements and helps prevent counterfeiting and contamination. Galibra Neuroscience advances personalized neurotherapies by leveraging AI-driven analysis and regulatory-compliant manufacturing processes. AI analyzes this data to predict how patients will respond to different treatments, enabling the development of customized therapies. AI can optimize the production of personalized drugs by predicting the most effective formulations and dosages for individual patients. It improves treatment outcomes and reduces adverse effects, leading to more precise and effective healthcare solutions. AI streamlines this process by automating the documentation and reporting required for regulatory submissions. ML algorithms can analyze regulatory guidelines and ensure that manufacturing processes and products adhere to these standards. AI-powered compliance solutions also monitor changes in regulatory requirements and update manufacturing protocols accordingly. This proactive approach reduces non-compliance risk and ensures manufacturers stay ahead of evolving regulatory landscapes. AI in pharmaceutical manufacturing is revolutionizing the industry by enhancing drug discovery, predictive maintenance, quality control, process optimization, supply chain management, personalized medicine, and regulatory compliance. The advancements lead to more efficient, reliable, and cost-effective production processes, improving patient outcomes and advancing healthcare innovation. ...Read more
 The landscape of pharmaceutical discovery has been transformed by the rise and ongoing advancement of high-throughput screening (HTS) and automation technologies. The ability to rapidly and efficiently test large libraries of chemical compounds against biological targets has become essential in the search for new therapies. Today, HTS, powered by automation, is central to early-stage drug discovery, accelerating the identification of promising lead compounds and laying the groundwork for future breakthrough treatments. The synergy between HTS and automation is fundamental to the efficiency and success of modern drug discovery processes. Automation integrates a diverse range of robotic systems and software solutions to manage the repetitive and labor-intensive tasks inherent in HTS, enhancing both accuracy and throughput while minimizing human error. One key area is compound management, where automated systems leverage robotic arms and advanced software to store, retrieve, and prepare compound libraries with precision. These technologies facilitate the accurate aliquoting of compounds into microplate formats, ensuring consistency across assays. In liquid handling, automation plays a critical role through the use of sophisticated pipetting systems that dispense precise volumes of liquids—ranging from assay reagents to cells and test compounds—into microplates. These systems, with their unwavering precision, can vary from basic multi-channel pipettes to complex robotic platforms capable of managing nanoliter volumes with high accuracy. Similarly, the execution of assays is streamlined through automated incubation, mixing, and detection processes. Robotic arms transfer microplates between instruments such as incubators—calibrated to maintain specific environmental conditions—and various readers that detect assay endpoints, including fluorescence, luminescence, and absorbance. Recent Advancements and Trends in HTS and Automation HTS and automation is constantly evolving to improve efficiency, data quality, and tackle complex biological questions. Recent trends include miniaturization and microfluidics, label-free detection technologies, integration with AI and Machine Learning, High-Content Screening (HCS), automation of complex biological models, increased focus on data quality and reproducibility, and cloud computing and data management. Miniaturization and microfluidics enable precise control over fluid flow and mixing, enabling complex cellular assays and studying biological processes. Label-free detection methods, such as surface plasmon resonance and bio-layer interferometry, provide physiologically relevant data for protein-protein interactions and drug binding kinetics. AI and ML are transforming HTS by enabling intelligent compound library design, predictive modeling, automated image analysis, and sophisticated data mining. Impact on Pharmaceutical Innovation HTS and automation have significantly accelerated drug discovery by reducing time, increasing the probability of finding active compounds, and reducing costs. HTS can screen diverse compound libraries, identify novel drug targets and mechanisms of action, and improve lead compound quality. The initial investment in HTS infrastructure, while significant, can lead to long-term cost savings, providing a reassuring financial benefit. It also facilitates the identification of compounds with desirable properties. HTS and automation, the bedrock of modern pharmaceutical innovation, hold immense potential. Their capacity to swiftly and effectively screen extensive chemical spaces against biological targets has significantly hastened the identification of lead compounds. The ongoing progress in miniaturization, label-free detection, AI integration, and the automation of complex biological models is poised to further amplify the potency and influence of HTS. This progression fuels the excitement for the discovery of groundbreaking medicines to meet unmet medical needs. The future of pharmaceutical discovery is intricately tied to the continuous evolution and application of these potent technologies, promising a future. ...Read more
Automation and artificial intelligence have greatly expanded their reach, driving the pharmaceutical regulatory affairs sector to gear up for integrating cutting-edge technologies with human expertise. The development of artificial intelligence (AI) in the life sciences sector is significantly transforming the pharmaceutical industry. Current initiatives aim to enhance and accelerate regulatory affairs by incorporating automated processes and leveraging technologies such as generative AI, machine learning (ML), natural language processing (NLP), and large language models (LLMs). Given these technological advancements, what implications does this altered landscape hold for regulatory teams and their operational processes? Essentially, the focus has transitioned towards utilizing automation to enhance the capabilities of regulatory professionals, resulting in the development of what is referred to as 'the augmented regulatory worker.' What Does Augmentation Look Like? Pharmaceutical companies need to assess the characteristics of the automated tasks involved to determine the ideal degree of enhancement necessary to improve human skills and productivity. For instance, repetitive and low-complexity tasks are ideally suited for complete automation through the use of bots, rule-based algorithms, or integrated operational systems. Conversely, as the complexity of tasks escalates—such as in data extraction, transformation, pattern recognition, and content creation—technologies like AI, ML, NLP, and LLM provide significant advantages in streamlining operations. These semi-automated processes still necessitate expert validation and final approval by a regulatory professional. Generative AI The past year has prominently featured Generative AI, making it essential to examine the potential impact of this technology on enhancing regulatory workforce capabilities. Despite being in its nascent phase, the anticipated benefits are considerable. Generative AI can significantly enhance the regulatory field by streamlining data mining, analytics, software operations, and content generation. By improving these processes, AI has the potential to alleviate the workload on professionals while increasing the efficiency and accuracy of strategic risk evaluations, predictive analyses of regulatory results, and interactions with health authorities. Integrated Solutions It is essential to prioritize integrated platforms that can enhance and unify processes derived from diverse internal and external regulatory intelligence sources. In addition to the collection of regulatory intelligence, an improved methodology positively impacts the publishing workflow within regulatory affairs. Such solutions, along with their sophisticated automation features, can notably increase the efficiency of manual bookmarking and hyperlinking tasks involved in this process. ...Read more

Weekly Brief